DR. TINA S. NOVA

Corporate Board Profile

Tech Score: 0/100

Azenta, Inc.

Filing Date	Source Excerpt
2024-12-17	Tina S. Nova \| Age 71 \| (Director since January 2023) Committees: Environmental, Social and Governance, Human Resources and Compensation Other Current Public Boards: Exagen, Inc. (NASDAQ: XGN) Former Public Boards: Veracyte Inc. (NASDAQ: VCYT), Arena Pharmaceuticals Inc. (ARNA) (Acquired by Pfizer, Inc.) Education: BS, The University of California, Irvine; PhD, The University of California, Riverside; Postdoctoral Research, New York University Medical Center Career Highlights: Ms. Nova has extensive experience in the creation of start-up companies and the commercialization of products with a focus on molecular diagnostics. Ms. Nova spent 15 years as the co-founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co-founded a number of early-stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc. Key Expertise Provided to the Board: Ms. Nova is an industry veteran in life sciences, with experience in building and leading successful life science businesses from conception through IPO, including public-company CEO experience. She has deep insights into commercial operations, sales and marketing efforts and brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, sold to Veracyte (NASDAQ: VCYT) in 2021, Molecular Stethoscope and Genoptix, which she co-founded and oversaw its $470 million sale to Novartis AG (NYSE: NVS) in 2011. Key Skills: Executive Leadership in Life Sciences/Healthcare, Public company executive experience, Global Business experience, Operational Experience, Growth Strategy and Market Expansion, M&A and Integration Experience Compensation: $262,517 total annual compensation.

Filing Date

Source Excerpt

2024-12-17

Tina S. Nova | Age 71 | (Director since January 2023) Committees: Environmental, Social and Governance, Human Resources and Compensation Other Current Public Boards: Exagen, Inc. (NASDAQ: XGN) Former Public Boards: Veracyte Inc. (NASDAQ: VCYT), Arena Pharmaceuticals Inc. (ARNA) (Acquired by Pfizer, Inc.) Education: BS, The University of California, Irvine; PhD, The University of California, Riverside; Postdoctoral Research, New York University Medical Center Career Highlights: Ms. Nova has extensive experience in the creation of start-up companies and the commercialization of products with a focus on molecular diagnostics. Ms. Nova spent 15 years as the co-founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co-founded a number of early-stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc. Key Expertise Provided to the Board: Ms. Nova is an industry veteran in life sciences, with experience in building and leading successful life science businesses from conception through IPO, including public-company CEO experience. She has deep insights into commercial operations, sales and marketing efforts and brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, sold to Veracyte (NASDAQ: VCYT) in 2021, Molecular Stethoscope and Genoptix, which she co-founded and oversaw its $470 million sale to Novartis AG (NYSE: NVS) in 2011. Key Skills: Executive Leadership in Life Sciences/Healthcare, Public company executive experience, Global Business experience, Operational Experience, Growth Strategy and Market Expansion, M&A and Integration Experience Compensation: $262,517 total annual compensation.

Data sourced from SEC filings. Last updated: 2026-02-03